Safety and efficacy of inhaled corticosteroids (ICS) in children with asthma

Journal of Asthma

Volumn 45, Issue SUPPL. 1, 2008, Pages 1-9

  Petrisko, Maria A ^a   Skoner, Jonathan D ^b   Skoner, David P ^c,d  

^a DUQUESNE UNIVERSITY   (United States)

^b JUNIATA COLLEGE   (United States)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Asthma; Bone density; Bone growth; Cataract; Children; Efficacy; Glaucoma; Hypothalamic pituitary adrenal axis; Inhaled corticosteroids; Safety

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CHLOROFLUOROCARBON; CICLESONIDE; CORTICOSTEROID DERIVATIVE; CROMOGLYCATE DISODIUM; FLUORINATED HYDROCARBON; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; MONTELUKAST; NEDOCROMIL; PLACEBO; PREDNISOLONE; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TRIAMCINOLONE ACETONIDE;

ADRENAL SUPPRESSION; AGE DISTRIBUTION; ASTHMA; BONE DENSITY SUPPRESSION; BONE DISEASE; BONE GROWTH SUPPRESSION; CATARACT; CHILDHOOD DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CUSHING SYNDROME; DERMAL THINNING; DIABETES MELLITUS; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; ENDOCRINE DISEASE; ENVIRONMENTAL FACTOR; GLAUCOMA; GROWTH RETARDATION; HEREDITY; HUMAN; HYPOTHALAMO PITUITARY ADRENAL FUNCTION SUPPRESSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INHALER; INTRAOCULAR HYPERTENSION; LOW DRUG DOSE; MUSCLE WEAKNESS; PATIENT COMPLIANCE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEX DIFFERENCE; SKIN DISEASE; SUBCAPSULAR CATARACT; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ASTHMA; BONE DENSITY; CHILD; GROWTH; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM;

EID: 58149084035     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.1080/02770900802631361     Document Type: Review

References (62)

1. National Asthma Education and Prevention Program. NAEPP Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma - Full Report 2007. Bethesda, MD: National Institutes of Health, National Heart, Lung and Blood Institute; August 2007.
2. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2007. Available at http://www.ginasthma.org.
3. Jeffery PK, Godfrey RW, Adelroth E, et al. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. Am Rev Respir Dis 1992; 145:890-899.
4. Rao VU, Apter AJ. Steroid phobia and adherence - problems, solutions, impact on benefit/risk profile. In: Skoner DP. Immunol Allergy Clin North America (Elsevier Saunders) 2005; 25(#3):581-596.
5. Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002 Mar; 109(3):410-8.
6. Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, Zeiger RS, Larsen G, Spahn JD, Bacharier LB, Bloomberg GR, Guilbert TW, Heldt G, Morgan WJ, Moss MH, Sorkness CA, Taussig LM. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115(2):233-242.
7. Chalmers GW, Macleod KJ, Little SA, et al. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002 Mar; 57(3):226-230.
8. Peters-Golden M, Swern A, Bird SS, et al. Influence of body mass index on the response to asthma controller agents. Eur Respir J 2006; 27:495-503.
9. Tantisira KG, Lake S, Silverman ES, et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet 2004 Jul 1; 13(13):1353-1359.
10. Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006; 354(19):1985-1997.
11. Wilson AM, McFarlane LC, Lipworth BJ. Systemic bioavailability profiles of oral prednisolone and nebulized budesonide in adult asthmatics. Chest 1998; 114(4):1022-1027.
12. Skoner DP, Rachelefsky GS, Meltzer EO, Chervinsky P, Morris RM, Seltzer JM, Storms WW, Wood RA. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics, 2000; 105:E23.
13. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med 1999; 159(9):941-955.
14. Szefler S, Rohatagi S, Williams J, Lloyd M, Kundu S, Banerji D. Ciclesonide, a Novel Inhaled Steroid, Does Not Affect Hypthalamic-Pituitary- Adrenal Axis function in Patients With Moderate-to-Severe Persistent Asthma. Chest 2005; 128:1104-1114.
15. Todd G, Dunlop K, McNaboe J, Ryan MF, Carson D, Shields MD. Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Lancet 1996; 348(9019):27-29.
16. Kewley GD. Possible association between beclomethasone diproprionate aerosol and cataracts. Aust Paediatr J 1980 Jun; 16(2):117-118.
17. Black RL, Oglesby RB, Von Sallmann L, Bunim JJ. Posterior subcapsular cataracts induced by corticosteroids in patients with rheumatoid arthritis. JAMA 1960 Sep 10; 174:166-171.
18. Simons FER, Persaud MP, Gillespie CA, et al. Absence of posterior subcapsular cataracts in young patients treated with inhaled glucocorticoids. Lancet 1993; 342:776-778.
19. Urban RC Jr, Cotlier E. Corticosteroid-induced cataracts. Surv Ophthalmol 1986 Sep-Oct; 31(2):102-10.
20. Bielory L. Ocular toxicity of systemic asthma and allergy treatments. Curr Allergy Asthma Rep 2006 Jul; 6(4):299-305.
21. Agertoft L, Larsen FE, Pedersen S. Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide. Eur Respir J 1998; 12(1):130-135.
22. Volovitz B, Amir J, Malik H, Kauschansky A, Varsano I. Growth and pituitary-adrenal function in children with severe asthma treated with inhaled budesonide. N Engl J Med 1993 Dec 2; 329(23):1703-8.
23. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997; 337(1):8-14.
24. Garbe E, LeLorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997; 277(9):722-727.
25. Mitchell P, Smith W, Chey T, Healey PR. Open-angle glaucoma and diabetes: the Blue Mountains eye study, Australia. Ophthalmology 1997 Apr; 104(4):712-8.
26. Wolff AH, Adelsberg B, Aloia J, Zitt M. Effect of inhaled corticosteroid on bone density in asthmatic patients: a pilot study. Ann Allergy 1991 Aug; 67(2 Pt 1):117-21.
27. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001 Sep 27; 345(13):941-7.
28. Ducharme FM, Chabot G, Polychronakos C, Glorieux F, Mazer B. Safety profile of frequent short courses of oral glucocorticoids in acute pediatric asthma: impact on bone metabolism, bone density, and adrenal function. Pediatrics 2003 Feb; 111(2):376-83.
29. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl JMed 2000 Oct; 343(15):1054-63.
30. Kelly HW, Van Natta ML, Covar RA, Tonascia J, Green RP, Strunk RC. CAMP Research Group. Effect of long-term corticosteroid use on bone mineral density in children: a prospective longitudinal assessment in the Childhood Asthma Management Program (CAMP) study. Pediatrics 2008 Jul; 122(1):e53-61.
31. van Staa TP, Cooper C, Leufkens HG, Bishop N. Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res 2003; 18(5):913-918.
32. Schlienger RG, Jick SS, Meier CR. Inhaled corticosteroids and the risk of fractures in children and adolescents. Pediatrics 2004; 114(2):469-473.
33. Food and Drug Administration. Guidance for Industry: Orally Inhaled and Intranasal Corticosteroids: Evaluation of the Effects on Growth in Children - updated March 2007. Available from: http://www.fda.gov/cder/guidance/3787dft. pdf.
34. Covar RA, Leung DY, McCormick D, et al. Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. J Allergy Clin Immunol 2000; 106:651-9
35. Martin RJ, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 2002 May 15; 165(10):1377-83.
36. Verberne AA, Frost C, Duiverman EJ, Grol MH, Kerrebjin KF. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group. Am J Respir Crit Care Med 1998 Jul; 158(1):213-19.
37. Heuck C, Wolthers OD, Kollerup G, Hansen M, Teisner B. Adverse effects of inhaled budesonide (800 micrograms) on growth and collagen turnover in children with asthma: A double-blind comparison of once-daily versus twice-daily administration. J Pediatr 1998; 133(5):608-612.
38. Heuck C, Heickendorff L, Wolthers OD. A randomised controlled trial of short term growth and collagen turnover in asthmatics treated with inhaled formoterol and budesonide. Arch Dis Child 2000; 83(4):334-339.
39. Pedersen S. Clinical safety of inhaled corticosteroids for asthma in children: An update of long-term trials. Drug Saf 2006; 29(7):599-612.
40. Skoner DP, Welch M, Tinkelman D, Bagchi P, Raudenbush MA, Banerji D. Inhaled corticosteroid-induced growth retardation in asthmatic children in a "real world" setting. J Allergy Clin Immunology 1999; 103:S61.
41. Tinkelman DG, Reed CE, Nelson HS, Offord KP. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics 1993; 92:64-77.
42. Doull IJ, Freezer NJ, Holgate ST. Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate. Am J Respir Crit Care Med 1995; 151(6):1715-1719.
43. Simons FER, and the Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. N Engl J Med 1997; 337:1659-1665.
44. Verberne AA, Frost C, Roorda RJ, van der Laag H, Kerrebijn KF. One year treatment with salmeterol compared with beclomethasone in children with asthma. The dutch paediatric asthma study group. Am J Respir Crit Care Med 1997; 156(3 Pt 1):688-695.
45. Pedersen S, Warner J, Wahn U, et al. Growth, systemic safety, and efficacy during 1 year of asthma treatment with different beclomethasone dipropionate formulations: An open-label, randomized comparison of extrafine and conventional aerosols in children. Pediatrics 2002; 109(6):e92.
46. Price JF, Russell G, Hindmarsh PC, et al. Growth during one year of treatment with .uticasone propionate or sodium cromoglycate in children with asthma. Pediatr Pulmonol 1997; 24:178-186.
47. Allen DB, Bronsky EA, LaForce CF, et al. Growth in asthmatic children treated with .uticasone propionate. Fluticasone propionate asthma study group. J Pediatr 1998; 132(3 Pt 1):472-477.
48. Schenkel EJ, Skoner DP, Bronsky EA, Miller D, Pearlman DS, Rooklin A, Rosen JP, Ruff ME, Vanderwalker ML, Wanderer A, Damaraju CV, Nolop KB, Messarina-Wicki, B. Absence of growth retardation in children with perennial allergic rhinitis following 1 year of treatment with mometasone furoate aqueous nasal spray. Pediatrics, 2000; 105:E22.
49. Skoner DP, Gentile D, Angelini B, Kane R, Birdsall D, Banerji D. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol 2003 Jan; 90(1):56-62.
50. Merkus PJ, van Essen-Zandvliet EE, Duiverman EJ, van Houwelingen HC, Kerrebijn KF, Quanjer PH. Long-term effect of inhaled corticosteroids on growth rate in adolescents with asthma. Pediatrics 1993; 91(6):1121-1126.
51. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88(5):373-381.
52. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000; 343(15):1064-1069.
53. Jonasson G, Carlsen KH, Jonasson C, Mowinckel P. Low-dose inhaled budesonide once or twice daily for 27 months in children with mild asthma. Allergy 2000; 55(8):740-748.
54. Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: A randomised, double-blind trial. Lancet 2003; 361(9363):1071-1076.
55. Skoner DP, Dunn M, Lee T. Effects of mometasone furoate dry powder inhaler on growth velocity and HPA axis function in children with asthma. Am J Respir Crit Care Med 2003; 167 (7): A272.
56. Becker, AB, Kuznetsova O, Vermeulen J, et al. Pediatric Montelukast Linear Growth Study Group. Linear growth in prepubertal asthmatic children treated with montelukast, beclomethasone, or placebo: a 56-week randomized double-blind study. Ann Allergy Asthma Immunol 2006 Jun; 96(6):800-7.
57. Skoner DP, Maspero J, Banerji, D, Ciclesonide Pediatric Growth Study Group. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics 2008 Jan; 121(1):e1-14.
58. Rohatagi S, Arya V, Zech K, Nave R, Hochhaus G, Jensen BK, et al. Population pharmacokinetics and pharmacodynamics of ciclesonide. J Clin Pharmacol 2003; 43(4):365-78.
59. Malozowski S. Comment on: Pediatrics 2008 Jan; 121(1):e1-14. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics 2008 Jul; 122(1):213; author reply 213.
60. Skoner DP. Balancing safety and effacacy in pediatric asthma management. Pediatrics 2002: 109(2):381-392
61. Kayani S, Shannon DC. Adverse behavioral effects of treatment for acute exacerbation of asthma in children: a comparison of two doses of oral steroids. Chest 2002 Aug; 122(2):624-8.
62. Chang AB, Clark R, Sloots TP, et al. A 5- versus 3-day course of oral corticosteroids for children with asthma exacerbations who are not hospitalised: a randomised controlled trial. Med J Aust 2008 Sep 15; 189(6):306-10.